Abstracts tagged "autoimmune diseases"

Abstract Number: 1937 • 2015 ACR/ARHP Annual Meeting
Dalazatide (ShK-186), a First-in-Class Blocker of Kv1.3 Potassium Channel on Effector Memory T Cells: Safety, Tolerability and Proof of Concept of Immunomodulation in Patients with Active Plaque Psoriasis
Ernesto J. Munoz-Elias¹, David Peckham¹, Kayla Norton¹, Judilyn Duculan², Inna Cueto², Xuan Li³, James Qin⁴, Kurt Lustig⁵, Eric Tarcha¹, Jared Odegard⁴, James G. Krueger² and Shawn P. Iadonato¹, ¹Kineta Inc, Seattle, WA, ²Rockefeller University, New York, NY, ³Rockefeller University, New York, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Kineta Inc., Seattle, WA
Background/Purpose: Effector memory T cells of both CD4 and CD8 lineages are key drivers of autoimmunity and are pathogenic in several autoimmune diseases including psoriasis,…
Abstract Number: 1947 • 2015 ACR/ARHP Annual Meeting
Hypermethylation of Treg-Specific Demethylated Regions in the Ikaros Transcription Factor Family Members, Helios and Eos, in Rheumatoid Arthritis Tregs
Alla Skapenko¹, Viktoria Soentgerath¹, Sonja Haupt², Jan Leipe¹ and Hendrik Schulze-Koops¹, ¹Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ²Division of Rheumatology and Clinical Immunology, Med.Klinik und Poliklinik IV, University of Munich, Munich, Germany
Background/Purpose: Foxp3 is the signature transcription factor of regulatory T cells (Tregs) and facilitates many of the characteristic functions of Tregs. Members of the Ikaros…
Abstract Number: 2101 • 2015 ACR/ARHP Annual Meeting
HLA Associations in Mothers of Children with Cardiac Manifestations of Neonatal Lupus
Hannah C. Ainsworth¹, Carl D. Langefeld¹, Miranda C. Marion², Nathalie Costedoat-Chalumeau³, Antonio Brucato⁴, Jill P. Buyon⁵ and Robert M. Clancy⁵, ¹Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ²Biostatistical Sciences and Center for Public Health Genomics, Wake Forest University Health Sciences, Winston-Salem, NC, ³Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁴Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Cardiac manifestations of neonatal lupus, comprising atrioventricular conduction defects and cardiomyopathy, occur in fetuses exposed to anti-Ro/SSA antibodies, and carry substantial mortality. There is…
Abstract Number: 233 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study
Mai Kawazoe, Kotaro Shikano, Kaichi Kaneko, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including systemic autoimmune diseases. Although glucocorticoids improve the outcome for patients with these diseases,…
Abstract Number: L4 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Munther Khamashta^1,2, Joan T. Merrill³, Victoria P. Werth^4,5, Richard Furie⁶, Kenneth Kalunian⁷, Gabor G. Illei⁸, Jorn Drappa⁸, Liangwei Wang⁸ and Warren Greth⁸, ¹Division of Women's Health, Graham Hughes Lupus Research Laboratory, King's College London, London, United Kingdom, ²Lambeth Wing, The Rayne Institute, St Thomas' Hospital London, London, United Kingdom, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Philadelphia VA Medical Center, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶North Shore-LIJ Health System, Lake Success, NY, ⁷UCSD School of Medicine, La Jolla, CA, ⁸MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Efficacy and safety of sifalimumab were assessed in a Phase 2b, randomized, double-blind, placebo (PBO)-controlled study in subjects with SLE (NCT01283139). Methods: Adults (n=431)…
Abstract Number: 2956 • 2014 ACR/ARHP Annual Meeting
Identification of Autoimmune Functional Variants Under Positive Selection in the Gullah African American Population of South Carolina
Paula S. Ramos¹, Satria Sajuthi², Jasmin Divers², Yiqi Huang³, Uma Nayak⁴, Wei-Min Chen⁴, Kelly J. Hunt⁵, Diane L. Kamen⁶, Gary S. Gilkeson⁶, Jyotika K. Fernandes⁷, Ida J. Spruill⁷, W. Timothy Garvey⁸, Michèle M. Sale³ and Carl D. Langefeld², ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Medicine and Center for Public Health Genomics, University of Virginia, Charlottesville, VA, ⁴Public Health Sciences, University of Virginia, Charlottesville, VA, ⁵Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁶Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁷Medical University of South Carolina, Charleston, SC, ⁸Department of Nutrition Sciences and Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose The reasons for the ethnic disparities in rheumatologic and autoimmune diseases (ADs) are largely unknown. We posit that population-specific selection influencing the allele frequencies…
Abstract Number: 2848 • 2014 ACR/ARHP Annual Meeting
T-Cell Signaling Defects Can be Corrected By Manipulating ‘TCR Signal Fine-Tuning Molecules’ That Are Altered Due to Increased Ubiquitination in Systemic Autoimmune Disease
Julia Pinkhasov¹ and Ram Raj Singh^1,2,3,4, ¹Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, ²Interdepartmental Program in Molecular Toxicology, UCLA, Los Angeles, CA, ³Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, ⁴Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA
Background/Purpose . T-cell selection in the thymus is primarily determined by the avidity of T cell receptor (TCR) for self-ligand-MHC. Since this process is dependent…
Abstract Number: 2779 • 2014 ACR/ARHP Annual Meeting
Systemic Inflammatory and Autoimmune Manifestations Associated with Myelodysplastic Syndrome: A French Multicenter Retrospective Study
Arsene Mekinian¹, Eric Grignano¹, Thorsten Braun², Olivier Decaux³, Eric Liozon⁴, Nathalie Costedoat-Chalumeau⁵, Jean Emmanuel Kahn⁶, Mohamed Hamidou⁷, Geraldine Falgarone⁸, Olivier Lortholary⁹, Sophie Park¹⁰, Zahir Amoura¹¹, A. Mathian¹², Bruno Gombert¹³, Christian Rose¹⁴, Xavier Puechal¹⁵, David Launay¹⁶, Guillaume Denis¹⁷, Bertrand Lioger¹⁸, Anne Laure Buchdaul¹⁹, Sophie georgin Lavialle²⁰, Francois Montestruc²¹, Mohammed Omouri²², Julien Rossignol²³, Jean Marc Ziza²⁴, Pascal Cathebras²⁵, Serge Madaule²⁶, Benoit de Wazières²⁷, Nathalie Morel¹⁵, Sebastien Trouillet²⁸, Loic Raffray²⁹, Yoland Schoindre³⁰, Eric Toussirot³¹, jean Charles Piette³², Claude Gardin², Lionel Ades³³, Pierre Fenaux³³ and Olivier Fain³⁴, ¹Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France, ²Haematology department Avicenne Hospital, bobigny, France, ³Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁴INTERNAL MEDICINE, DIJON, France, ⁵Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶Internal medicine Hopital Foch, PARIS, France, ⁷CHU Hôtel Dieu, Nantes, Nantes, France, ⁸Rheumatology department Avicenne Hospital INSERM 1125, bobigny, France, ⁹Service de maladies infectieuses, Hôpital Necker-Enfants malades, AP-HP, Paris, France, ¹⁰Haematology Department, Grenoble University Hospital, grenoble, France, ¹¹Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹²Internal Medecine Department, Pitie-Salpetriere Hospital, Paris, France, ¹³Internal Medicine, La Rochelle hospital, La Rochelle, France, ¹⁴haematology, lille, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁶Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁷Internal Medicine, Rochefoucault hospital, Rochefoucault, France, ¹⁸INTERNAL MEDICINE, tours, France, ¹⁹Internal Medicine, Douai hospital, Douai, France, ²⁰Internal Medicine Department Tenon Hospital, paris, France, ²¹exystat, PARis, France, ²²Rheumatology Department Romilly Hospital, romilly, France, ²³haematology, paris, France, ²⁴Hopital Croix-Saint-Simon, Paris Cedex 20, France, ²⁵Internal Medicine, University Hospital St Etienne, St Etienne, France, ²⁶Medecine interne, Chg, Albi, France, ²⁷Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, ²⁸INTERNAL MEDICINE, aurillac, France, ²⁹INTERNAL MEDICINE, bordeaux, France, ³⁰DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ³¹Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, ³²INTERNAL MEDICINE, PARIS, France, ³³Haematology department Saint Louis Hospital, paris, France, ³⁴Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France
Background/Purpose: To describe characteristics, treatment and outcome of patients with systemic inflammatory or autoimmune diseases (SAID) and myelodysplastic syndrome (MDS).Methods: For this retrospective study, a…
Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Iris Hecht¹, Kay McNamee², Aviad Keren³, Joseph R. Podojil⁴, Ilan Vaknin¹, Anat Oren¹, Galit Rotman¹, Eyal Neria¹, Stephen D. Miller⁴, Amos Gilhar³ and Richard O. Williams², ¹Compugen Ltd., Tel Aviv, Israel, ²Kennedy Institute of Rheumatology, Oxford University, Oxford, United Kingdom, ³Technion Institute of Technology, Haifa, Israel, ⁴Microbiology-Immunology, Northwestern University, Chicago, IL
Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…
Abstract Number: 2201 • 2014 ACR/ARHP Annual Meeting
Haematological Complications in Rheumatic Diseases: Not Only Lymphomas
Elena Elefante¹, Chiara Baldini¹, Alice Parma¹, Elisa Cioffi², Francesco Ferro¹, Roberta Vagelli², Martina Rousseau³, Rosaria Talarico², Sara Galimberti³ and Stefano Bombardieri², ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, Pisa, Italy, ³Hematology Unit, Pisa, Italy
Background/Purpose Several immunological abnormalities have been reported among patients affected by myelodisplastic syndrome (MDS). On the other hand, a relatively limited number of studies have…
Abstract Number: 2190 • 2014 ACR/ARHP Annual Meeting
Features of Interstitial Lung Disease Associated with Connective Tissue Disease in a Spanish Southwest Cohort
Adela Gallego Flores¹, Carmen Carrasco Cubero², Raul Veroz Gonzalez¹, Luz Maria Mellado Narciso¹, Tamara Libertad Rodriguez Araya¹, Juan Jose Aznar Sánchez¹ and Eugenio Chamizo Carmona¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Hospital de Merida, Mérida, Spain
Background/Purpose Diffuse interstitial lung disease (ILD) can be associated with connective tissue diseases (CTD), and can increase morbidity and mortality significantly. The predominant patterns of…
Abstract Number: 2182 • 2014 ACR/ARHP Annual Meeting
Investigating the Roles of Factor H-Related Proteins in Systemic Lupus Erythematosus (SLE) and Other Autoimmune Diseases
Alexandra Antonioli¹, Brandon Renner², Joshua Thurman³, V. Michael Holers⁴ and Jonathan Hannan⁴, ¹Department of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Renal Division, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose Complement plays a central role in the pathogenesis of systemic lupus erythematosus (SLE) wherein inappropriate activation of complement leads to substantial tissue damage, especially…
Abstract Number: 2167 • 2014 ACR/ARHP Annual Meeting
Snapin Is Critical for Cathepsin D Activation and the Normal Lysosomal Function
Bo Shi¹, Qi Quan Huang², Robert Birkett², Renee E. Koessler¹, Andrea Dorfleutner¹, Christian Stehlik¹ and Richard M. Pope¹, ¹Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose: Our recent data indicates that Snapin, a SNAP associated protein, is critical for maintaining healthy autophagy and monocytes to macrophage (MFs) differentiation which requires…
Abstract Number: 1359 • 2014 ACR/ARHP Annual Meeting
Care of Women with Rheumatological Conditions during Family Planning and Pregnancy
Megan E. B. Clowse¹, Munther Khamashta², Daphnee S. Pushparajah³ and Eliza Chakravarty⁴, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ³UCB Pharma, Brussels, Belgium, ⁴OMRF, Oklahoma City, OK
Background/Purpose Rheumatological diseases often affect women of reproductive age and can impact pregnancy outcomes. There is a need to understand how patients (pts) are managed…
Abstract Number: 1073 • 2014 ACR/ARHP Annual Meeting
Prescription Medication Trends in Medicaid-Enrolled Pregnant Women with Rheumatoid Arthritis, Psoriasis, and Systemic Lupus Erythematosus
Rishi Desai¹, Krista Huybrechts², Brian Bateman², Helen Mogun², Sonia Hernandez-diaz³ and Seoyoung C. Kim⁴, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Little is known about the trends of medication use in pregnant women with autoimmune disorders. The objective of the current study was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].